

**Tigard, OR/Los Angeles, CA** - Bioject Medical Technologies, Inc. ("Bioject") and The Covenant Group announce the formation of Bioject Israel LTD

Bioject Israel, LTD is the exclusive distributor of Bioject needle-free injection technologies in the State of Israel, providing a vital alternative to needle and syringe for the administration of liquid injectables.

"Despite the fact that needle free technology has been available for many years, it is only now gaining traction as a preferred method of administration in many parts of the world", said Amir Ness, President of Bioject Israel, LTD. "There are numerous ways in which Bioject stands out as the leader in needle free technology. In the years ahead, I think we're going to start seeing rapid adoption of this technology. We look forward to introducing Bioject's array of devices to the Israeli market and working with companies at the forefront of medicine and healthcare."

Commented Mark Logomasini, Bioject's President and CEO, "Having worked with Amir Ness on other ventures, we are very pleased that he has come aboard to represent Bioject in Israel. His knowledge of the region combined with his immersion in needle-free technology promises to be a highly effective combination and we look forward to a successful collaboration."

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

The Covenant Group  
Amir Ness  
433 N. Camden Dr. Suite 400  
Beverly Hills, Ca. 90210

Readers and potential investors are cautioned that an investment in the Bioject's securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on [www.otcmarkets.com](http://www.otcmarkets.com).

**For more information about Bioject visit [www.bioject.com](http://www.bioject.com).**